NCT04182100 2025-09-15
Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply
PharmaEssentia Japan K.K.
Phase 2 Completed
Clinical Trials
8 trialsNCT06290765 2025-07-31
PV
PharmaEssentia
Phase 4 Not yet recruiting
NCT04160546 2024-12-31
ResToP
Fundacion CRIS de Investigación para Vencer el Cáncer
Phase 2 Active not recruiting
NCT06002490 2024-11-08
A Study to Evaluate P1101 in Japanese PV Patients
PharmaEssentia Japan K.K.
Phase 3 Completed
NCT03003325 2024-09-19
Low-PV
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Phase 2 Completed
NCT04243122 2024-05-29
AIRPORT-MPN
Ottawa Hospital Research Institute
Phase 2 Completed
NCT01259817 2017-01-11
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT00940784 2014-11-26
ISCLAP
Icahn School of Medicine at Mount Sinai
Phase 2 Withdrawn